BiondVax reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy - read this article along with other careers information, tips and advice on BioSpace
BiondVax Pharma (BVXV) reports successful results in preclinical in vivo study of its innovative inhaled COVID-19 NanoAb therapy streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Hamsters infected with SARS-COV-2 and then treated with inhaled anti-COVID-19 NanoAbs demonstrated significantly less severe illness and faster recovery in comparison to infected hamsters treated with inhaled placebo.
/PRNewswire/ BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceuticals company focused on developing, manufacturing and commercializing innovative.